Alkem Laboratories DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.77×	0.82×	0.88×	0.90×	0.77×
	1.09×	1.09×	1.17×	1.04×	1.00×
	17.5%	17.8%	16.6%	15.4%	11.2%
	0.76×	0.76×	0.78×	0.86×	0.83×
	1.45×	1.45×	1.42×	1.45×	1.46×
	16.2%	17.7%	19.0%	17.9%	10.5%
	17.8%	17.8%	19.4%	18.6%	11.1%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ALKEM₹5,079.00

Alkem Laboratories Ltd.

· Pharma & Health

₹ CrorePeersMANKIND TORNTPHARM IPCALAB LUPIN FORTIS AUROPHARMA LAURUSLABS BIOCONMcap ₹60,719 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.77	0.90	0.88	0.82	0.77
Interest Burden (Pretax/EBIT) ×	1.00	1.04	1.17	1.09	1.09
EBIT Margin %	11.20	15.36	16.62	17.83	17.49
Asset Turnover ×	0.83	0.86	0.78	0.76	0.76
Financial Leverage (Assets/Equity) ×	1.46	1.45	1.42	1.45	1.45
ROE (5-step product, year-end total equity) %	10.50	17.88	18.96	17.67	16.16
ROE (owners' profit / average owners' equity) %	11.13	18.55	19.42	17.84	17.84

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.